Loading...
XSHE002675
Market cap1.44bUSD
Jan 15, Last price  
12.34CNY
1D
-0.64%
1Q
-0.64%
Jan 2017
-13.71%
IPO
119.18%
Name

Yantai Dongcheng Pharmaceuticl Gp Co Ltd

Chart & Performance

D1W1MN
XSHE:002675 chart
P/E
50.28
P/S
3.22
EPS
0.25
Div Yield, %
2.45%
Shrs. gr., 5y
1.70%
Rev. gr., 5y
7.02%
Revenues
3.28b
-8.58%
323,389,253376,458,482663,628,430857,572,997587,753,814774,730,022751,021,851794,915,7791,158,450,7361,595,601,1372,332,822,9372,992,761,0123,418,977,5483,912,049,9963,582,955,4273,275,647,886
Net income
210m
-31.75%
15,065,07031,988,49350,639,117127,934,504105,057,604100,849,519103,957,97789,745,422130,952,612264,730,181388,792,583293,640,391417,765,795260,849,859307,291,216209,735,777
CFO
277m
-72.21%
41,567,800057,016,632138,826,24244,535,233052,001,63966,687,654196,281,214208,935,413493,063,071696,375,864572,576,712943,581,205996,537,274276,944,524
Dividend
Jun 24, 20240.125 CNY/sh
Earnings
May 16, 2025

Profile

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API, chemical medicines, proprietary Chinese medicines, and nuclide drugs products in China. It offers heparin, chondroitin sulphate, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C for use in the therapeutic areas of cardiovascular, oncology, urology, orthopedics, and other therapeutic areas. The company also exports its products to approximately 40 countries and regions, including the Europe, America, Asia Pacific, and internationally. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is based in Yantai, China.
URL
http://www.dcb-group.com
IPO date
May 25, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,275,648
-8.58%
3,582,955
-8.41%
Cost of revenue
2,698,830
2,835,224
Unusual Expense (Income)
NOPBT
576,818
747,732
NOPBT Margin
17.61%
20.87%
Operating Taxes
83,065
92,760
Tax Rate
14.40%
12.41%
NOPAT
493,753
654,971
Net income
209,736
-31.75%
307,291
17.80%
Dividends
(258,335)
(120,332)
Dividend yield
1.71%
0.90%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
331,384
395,463
Long-term debt
271,343
247,664
Deferred revenue
233,291
240,273
Other long-term liabilities
223,340
2,220
Net debt
(274,726)
(569,592)
Cash flow
Cash from operating activities
276,945
996,537
CAPEX
(511,945)
Cash from investing activities
(602,801)
Cash from financing activities
(676)
FCF
186,202
528,784
Balance
Cash
664,533
1,048,950
Long term investments
212,919
163,770
Excess cash
713,670
1,033,572
Stockholders' equity
3,054,904
2,900,169
Invested Capital
5,730,243
5,029,270
ROIC
9.18%
12.90%
ROCE
8.93%
12.30%
EV
Common stock shares outstanding
824,757
807,806
Price
18.33
10.69%
16.56
4.94%
Market cap
15,117,801
13.01%
13,377,270
5.67%
EV
15,463,298
13,341,343
EBITDA
724,064
872,825
EV/EBITDA
21.36
15.29
Interest
59,319
58,641
Interest/NOPBT
10.28%
7.84%